Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose clinical studies

Pharmaceutical Research

Volumn 28, Issue 8, 2011, Pages 1963-1972

  Yamane, Naoe ^a   Tozuka, Zenzaburo ^b   Kusama, Makiko ^a   Maeda, Kazuya ^a   Ikeda, Toshihiko ^c   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SEKISUI CHEMICAL CO LTD   (Japan)

^c YOKOHAMA COLLEGE OF PHARMACY   (Japan)

Author keywords

cassette dosing; exploratory clinical trials; LC MS MS; lower limit of quantification; microdose study

Indexed keywords

AMFEBUTAMONE; AMLODIPINE; ATORVASTATIN; CANDESARTAN; CELECOXIB; CETIRIZINE; CITALOPRAM; CLOPIDOGREL; ESOMEPRAZOLE; IMATINIB; LANSOPRAZOLE; LEVOFLOXACIN; LOSARTAN; MONTELUKAST; OLANZAPINE; OSELTAMIVIR; PANTOPRAZOLE; PIOGLITAZONE; QUETIAPINE; RISPERIDONE; ROSIGLITAZONE; ROSUVASTATIN; SERTRALINE; SIMVASTATIN; TAMSULOSIN; TOPIRAMATE; UNINDEXED DRUG; VALSARTAN; VENLAFAXINE; ZOLPIDEM;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG ISOLATION; DRUG MICRODOSE; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PRODUCT RECOVERY; SENSITIVITY ANALYSIS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 79961169355     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0423-8     Document Type: Article

References (22)

1. European Agency for the Evaluation of Medicinal Products (EMEA). Position paper on the nonclinical safety studies to support clinical trials with a single microdose. CPMP/SWP2599/0.; 28 January 2003.
2. US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Guidance for industry, investigators, and reviewers exploratory IND studies.; January 2006.
3. Ministry of Health, Labour and Welfare (MHLW), Japan. Guidance on microdose clinical trial (Pharmaceutical and Food Safety Bureau Notification No. 0603001).; 2008.
4. J Gilbert P Henske A Singh 2003 Rebuilding big pharma's business model. Windhover's In Vivo Bus Med Rep 21 73 82
5. R Frank R Hargreaves 2003 Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 566 580 12838269 10.1038/nrd1130 1:CAS:528:DC%2BD3sXltVakt78%3D (Pubitemid 37361748)
6. L Suter LE Babiss EB Wheeldon 2004 Toxicogenomics in predictive toxicology in drug development Chem Biol 11 161 171 15123278 1:CAS:528:DC%2BD2cXhsleksr0%3D (Pubitemid 38300287)
7. N Yamane Z Tozuka Y Sugiyama T Tanimoto A Yamazaki Y Kumagai 2007 Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry J Chromatogr B 858 118 128 10.1016/j.jchromb.2007.08.011 1:CAS:528:DC%2BD2sXhtFCjs7fE (Pubitemid 47513599)
8. N Yamane T Takami Z Tozuka Y Sugiyama A Yamazaki Y Kumagai 2009 Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma Drug Metab Pharmacokinet 24 391 406 10.2133/dmpk.24.389
9. G Lappin RC Garner 2003 Big physics, small doses: the use of AMS and PET in human microdosing of development drugs Nat Rev Drug Discov 7 233 240 10.1038/nrd1037 (Pubitemid 37361669)
10. G Lappin RC Garner 2006 A review of human phase 0 (microdosing) clinical trials following the US food and drug administration exploratory investigational new drug studies guidance Int J Pharm Med 20 3 159 165 10.2165/00124363- 200620030-00002 (Pubitemid 44166665)
11. LS Zhu VN Lapko JW Lee YJ Basir C Kafonekm C Kafonekm C Briscoe 2006 A general approach for the quantitative analysis of biophosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry Rapid Commun Mass Spectr 20 3421 3426 10.1002/rcm.2755 1:CAS:528: DC%2BD28Xht1Grtr%2FJ (Pubitemid 44763942)
12. CU Kim W Lew MA Williams H Liu L Zhang S Swaminathan N Bischofberger MS Chen DB Mendel CY Tai WG Laver RC Stevens 1997 Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity J Am Chem Soc 119 681 690 16526129 10.1021/ja963036t 1:CAS:528:DyaK2sXitFWjuw%3D%3D (Pubitemid 27101232)
13. K Yamatsugu S Kamijo Y Suto M Kanai M Shibasaki 2007 A concise synthesis of Tamiflu: third generation route via the Diels-Alder reaction and the Curtius rearrangement Tetrahedron Lett 48 1403 1406 10.1016/j.tetlet.2006.12.093 1:CAS:528:DC%2BD2sXht1ajtL4%3D (Pubitemid 46136390)
14. Y Lu H Wen W Li Y Chi Z Zhang 2004 Determination of donepezil hydrochloraide (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, chinese subjects J Chromatogr Sci 42 234 237 15189594 1:CAS:528:DC%2BD2cXksVSnu7k%3D
15. AY Yang L Sun DG Musson JJ Zhao 2005 Application of a novel ultra-low elution volume 96-well solid-phase extraction method to the LC/MS/MS determination of simvastatin and simvastatin acid in human plasma J Pharm Biomed 38 521 527 10.1016/j.jpba.2005.01.016 1:CAS:528:DC%2BD2MXltVegurw%3D (Pubitemid 40733190)
16. J Posner A Bye K Dean AW Peck PD Whiteman 1985 The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses Eur J Clin Pharmacol 29 97 103 3932079 10.1007/BF00547376 1:CAS:528:DyaL28XhsVCntg%3D%3D (Pubitemid 15232084)
17. M Ohtawa N Uchiyama Y Saito A Suzuki C Tanno N Nakaya Y Goto 1989 Phase I study of MK-733, an inhibitor of HMG-CoA reductase II: pharmacokinetics of MK-733 in healthy subjects after single and multiple oral administration J Clin Ther Med 5 6 1123 1140
18. M Nakashima M Kanamaru T Uematsu K Takayama K Kamei 1995 Phase I study of MK-954, a new angiotensin II receptor antagonist-results of single oral administration Jap J Clin Pharmacol Ther 26 671 684 1:CAS:528:DyaK2MXpt12nsrs%3D
19. Ministry of Health, Labour and Welfare (MHLW), Japan. Guidelines for Bioequivalence Studies of Generic Products (Pharmaceutical and Food Safety Bureau Notification No.1124004).; 2006.
20. G Lappin W Kuhnz R Jochemsen J Kneer A Chaudhary B Oosterhuis WJ Drijfhout M Rowland RC Garner 2006 Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs Clin Pharmacol Ther 80 203 215 16952487 10.1016/j.clpt.2006.05.008 1:CAS:528: DC%2BD28XptFCgu7w%3D (Pubitemid 44313903)
21. European Union Microdose AMS Partnership Programme (EUMAPP). Outcomes from EUMAPP-A study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics - 2009.
22. US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Guidance for industry, bioanalytical method validation.; May 2001.